Oura has received an equity investment from Eli Lilly and Company to accelerate the development of health tools that connect biometric information, daily behaviors and medical treatments. Financial terms of the investment were not disclosed.
The investment brings together Oura’s wearable health technology and Lilly’s experience developing medicines for chronic conditions. Oura plans to use the additional capital to create more personalized tools that help people understand how their sleep, activity, stress, recovery and other physiological patterns change throughout their care journeys.
Oura believes healthcare is moving toward a more connected model in which medical treatments are supported by continuous health information and guidance between clinical appointments.
Traditional healthcare data is often collected during isolated medical visits. Wearable devices can provide a broader view by measuring patterns over days, weeks and months as users go about their everyday lives.
Oura’s platform is designed to help members understand how behaviors and routines affect their overall health. The company’s wearable ring collects biometric signals that are translated into insights through the Oura App.
These insights can help users identify changes in sleep quality, activity levels, physiological stress and recovery. Oura believes connecting these patterns with medication use and other health information could give people a more complete understanding of how their bodies respond over time.
The opportunity is particularly relevant in metabolic health as more patients use GLP-1 therapies to manage conditions such as obesity and diabetes.
More than 100,000 Oura members have recorded GLP-1 use within the Oura App, providing the company with a substantial user base interested in understanding how treatment may relate to their daily routines and biometric trends.
Oura recently introduced GLP-1 Insights, a companion experience that combines wearable data with information specifically related to GLP-1 use.
Members can log their medication use and compare it with changes in sleep, activity, stress, recovery and other physiological measurements.
The feature is intended to provide additional context rather than focusing on a single health metric. A user may be able to observe how routines and biometric patterns evolve during treatment and use that information to remain engaged with long-term health goals.
GLP-1 medications can be one component of a broader care plan that may also involve nutrition, physical activity, sleep and behavioral changes.
Oura believes digital health tools can support patients between medical appointments by helping them recognize patterns, maintain routines and stay connected with their progress.
The investment from Lilly will provide Oura with additional resources to develop this broader ecosystem of health experiences.
The companies did not disclose whether the transaction includes a commercial partnership, product integration or formal research agreement. Oura described the investment as aligned with its vision of making care more connected, personalized and responsive to how people live.
The transaction reflects growing interest from pharmaceutical companies in digital health platforms capable of supporting patients throughout the complete treatment journey.
Medicines are often evaluated through clinical outcomes measured at specific intervals. Wearable technology can add continuous information about everyday health behaviors and physiological responses.
This data could help people better understand their individual experiences, although wearable measurements are not substitutes for professional medical advice or clinical testing.
For Oura, the Lilly investment could support the development of additional tools focused on chronic conditions and treatment-related health journeys.
The company may also be able to create more personalized experiences based on the relationship between biometric trends, user-reported information and daily behaviors.
Oura’s approach emphasizes that health is not defined by one reading or event. Instead, health develops through recurring patterns involving sleep, movement, stress, recovery and other factors.
By presenting these patterns over time, the company aims to help users make more informed decisions and remain motivated throughout their care.
The investment also highlights the expanding role of consumer health technology within the broader healthcare system.
Wearable devices initially focused heavily on fitness tracking. Newer platforms are increasingly being used to support preventative health, chronic condition management and communication between patients and healthcare providers.
Oura believes the future of care will combine medical treatment with tools that help people understand what is happening in their bodies outside traditional healthcare settings.
The company intends to use Lilly’s investment to accelerate that vision and build health experiences that are more deeply integrated into users’ daily lives.
